GFRα4 Protein - GDNF Family Receptor Alpha 4

📖 Wiki Page

protein1489 wordssynced 2026-04-02

GFRα4 Protein - GDNF Family Receptor Alpha 4

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GFRα4 Protein - GDNF Family Receptor Alpha 4</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GFRA4</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GFRα4 - GDNF Family Receptor Alpha 4</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GFRA4" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Gfrα4 Protein Gdnf Family Receptor Alpha 4 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

GFRα4 Protein - GDNF Family Receptor Alpha 4

Introduction

Overview

GFRα4 (GDNF Family Receptor Alpha 4) is the most recently identified member of the GFRα (GDNF Family Receptor Alpha) family of proteins, which are critical for the survival and maintenance of specific neuronal populations in the central and peripheral nervous systems. GFRα4 serves as the primary high-affinity receptor for the neurotrophic factor persephin (PSPN), though it also exhibits binding affinity for other GDNF family ligands. Unlike other GFRα family members, GFRα4 demonstrates unique ligand binding specificity and expression patterns that make it a promising therapeutic target for specific neurodegenerative diseases. [@gdnf2002]

The GFRα4 protein is a glycosylphosphatidylinositol (GPI)-anchored protein that can signal through both RET-dependent and RET-independent mechanisms. This versatility allows for nuanced control of neuronal survival pathways and provides opportunities for therapeutic modulation. [@persephin1999]

Molecular Characteristics

Structure

The GFRα4 protein possesses several structural features that define its function: [@persephin1996]

Molecular Weight: Approximately 42-45 kDa
Amino Acid Length: 377-401 amino acids (species-dependent)
Protein Family: GDNF family receptor alpha
Gene Symbol: GFRA4
UniProt Accession: Q9H3R5 (human)

Protein Domains

The protein structure includes: [@gdnf2018]

Signal Peptide: N-terminal signal sequence for proper membrane targeting

Cysteine-Rich Domain (CRD): Three conserved cysteine-rich domains that form the ligand-binding pocket

GPI Anchor Signal: C-terminal sequence for membrane attachment via glycosylphosphatidylinositol

N-linked Glycosylation Sites: Multiple glycosylation sites affecting protein folding and stability

Ligand Binding Specificity

GFRα4 exhibits unique binding characteristics: [@persephin1998]

Primary Ligand: Persephin (PSPN) - highest affinity
Secondary Ligand: GDNF (lower affinity)
Tertiary: Neurturin and artemin (minimal binding)
Binding Affinity: Kd ~10-50 nM for persephin

This narrow ligand specificity distinguishes GFRα4 from other family members (GFRα1-3), which show broader ligand recognition. [@persephin1999a]

Signal Transduction Mechanisms

RET-Dependent Signaling

When GFRα4 binds persephin, it can recruit and activate the RET (REarranged during Transfection) receptor tyrosine kinase: [@persephintreated2001]

Ligand Binding: Persephin binds to GFRα4, inducing conformational changes

RET Recruitment: The GFRα4-persephin complex recruits RET to the membrane

Dimerization: RET undergoes dimerization and autophosphorylation

Signal Activation: Multiple downstream pathways are activated:

PI3K/Akt Pathway: Promotes cell survival, inhibits [apoptosis](/entities/apoptosis)
MAPK/ERK Pathway: Supports neuronal differentiation and plasticity
PLCγ Pathway: Modulates calcium signaling and synaptic function

RET-Independent Signaling

GFRα4 can also signal independently of RET through: [@persephin2001]

Src Family Kinases: Direct activation of Src family members

Integrin Signaling: Interaction with integrin receptors

GPI-Anchored Protein Clusters: Formation of signaling complexes in lipid rafts

This RET-independent signaling provides redundancy and allows for neurotrophic support even in cells with low RET expression. [@persephin2003]

Expression Pattern

Central Nervous System

GFRα4 expression in the brain is more restricted than other GFRα family members:

Brainstem: Moderate expression in motor and sensory nuclei
Spinal Cord: Expression in ventral horn motor [neurons](/entities/neurons)
Cerebellum: Purkinje cell layer expression
[Hippocampus](/brain-regions/hippocampus): Limited expression in CA regions
[Cortex](/brain-regions/cortex): Layer-specific expression in cortical neurons

Peripheral Nervous System

Dorsal Root Ganglia: Primary sensory neuron expression
Sympathetic Ganglia: Postganglionic neuron expression
Enteric Nervous System: Subset of enteric neurons

Non-Neuronal Tissues

Kidney: Collecting duct cells
Lung: Bronchial epithelium
Testis: Spermatogenic cells
Thyroid: Follicular cells

Role in Neurodegenerative Diseases

Parkinson's Disease

The persephin/GFRα4/RET signaling axis is highly relevant to Parkinson's disease:

Dopaminergic Neuroprotection

Persephin protects dopaminergic neurons in the substantia nigra pars compacta
GFRα4 is expressed in ventral midbrain dopaminergic neurons
Activation of Akt pathway promotes survival against MPTP toxicity
May support dopamine neuron function more selectively than GDNF

Therapeutic Potential

Unlike GDNF, persephin does not cause weight loss or adverse effects
Can cross the blood-brain barrier more efficiently
May promote dopamine release and synaptic function
Potential for preventing Lewy body formation

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Protection

Persephin protects both upper and lower motor neurons
GFRα4 is expressed in spinal cord motor neurons
Delays disease onset in SOD1 mouse models
Supports axonal integrity and neuromuscular junction maintenance

Mechanisms

Activation of anti-apoptotic pathways (Bcl-2, Bcl-xL)
Reduction of excitotoxicity
Support of mitochondrial function
Modulation of neuroinflammation

Alzheimer's Disease

While less studied, GFRα4 may have roles in:

Cholinergic neuron survival (basal forebrain)
Synaptic plasticity in hippocampus
Potential for cognitive function support
Possible interaction with amyloid pathology

Peripheral Neuropathy

Diabetic Neuropathy

Protects sensory neurons from hyperglycemic damage
Supports nerve regeneration
May improve nerve conduction velocities

Chemotherapy-Induced Neuropathy

Protects against taxol and vincristine toxicity
Supports axonal transport
Potential for combination therapies

Therapeutic Implications

Persephin-Based Therapies

Persephin (PSPN) is the primary therapeutic agent targeting GFRα4:

Advantages over GDNF

Better CNS penetration
Reduced side effects (no weight loss)
More selective action via GFRα4
Broader therapeutic window

Delivery Methods

Recombinant protein administration
Gene therapy (AAV-mediated)
Cell-based delivery (engineered cells)
Small molecule mimetics (in development)

GFRα4 Agonists

Small Molecule Approaches

Development of GFRα4-selective agonists
Non-peptide compounds for oral bioavailability
Brain-penetrant candidates

Combination Therapies

GDNF + persephin for additive effects
With neurotrophic factors (BDNF, CNTF)
With anti-inflammatory agents

Gene Therapy Strategies

Viral Vectors

AAV vectors for persephin expression
Targeted delivery to affected neuron populations
Regulated expression systems

Cell-Based Therapy

Engineered cells secreting persephin
Encapsulated cell devices
Autologous cell modification

Animal Models

Transgenic Models

GFRA4 knockout mice: Viable with subtle neurological phenotypes
Persephin knockout mice: Mild motor coordination deficits
Double knockouts: Synergistic effects on neuronal populations

Disease Models

MPTP Parkinson's model: Protection with persephin
6-OHDA model: Recovery of dopaminergic function
SOD1 ALS model: Delayed disease progression
STZ diabetic neuropathy: Improved nerve function

Clinical Development

Status

GFRα4-targeted therapies are in preclinical development:

Persephin: GMP production established
GFRα4 agonists: Lead optimization ongoing
Gene therapy: Preclinical validation

Challenges

Limited understanding of human GFRα4 distribution
Optimal delivery route determination
Biomarker development for patient selection
Combination therapy protocol optimization

Research Directions

Current Focus Areas

Structural Studies: Understanding ligand-receptor interactions at atomic level

Signaling Pathways: Elucidating RET-independent mechanisms

Biomarkers: Identifying responders to therapy

Delivery: Improving brain penetration

Combination: Synergistic approaches with other neurotrophic factors

Emerging Areas

[Blood-Brain Barrier](/entities/blood-brain-barrier) Modulation: Enhancing CNS delivery
Patient Stratification: Genetic markers for response
Disease-Modifying Potential: Beyond neuroprotection
Repurposing Opportunities: Other neurological conditions

Background

The study of Gfrα4 Protein Gdnf Family Receptor Alpha 4 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-References

[GFRA4 Gene](/proteins/gfra4-protein) - Gene encoding GFRα4
[Persephin Protein](/proteins/persephin-protein) - Primary ligand
[RET Receptor](/proteins/ret-receptor) - Signaling co-receptor
[GDNF Family](/mechanisms/gdnf-family-signaling) - Related signaling
[Parkinson's Disease](/diseases/parkinsons-disease) - Primary therapeutic target
[ALS](/diseases/amyotrophic-lateral-sclerosis) - Motor neuron disease
[Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy) - Treatment approaches
[Motor Neuron Disease](/diseases/motor-neuron-disease) - Disease category

External Links

[UniProt: Q9H3R5](https://www.uniprot.org/uniprot/Q9H3R5)
[NCBI Gene: GFRA4](https://www.ncbi.nlm.nih.gov/gene/64054)
[HGNC: GFRA4](https://www.genenames.org/data/hgnc_data.php?hgnc_id=13949)
[Ensembl: GFRA4](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125861)
[PubMed: Persephin and GFRα4](https://pubmed.ncbi.nlm.nih.gov/?term=persephin+GFRA4+neurodegeneration)

References

[^1] Baloh RH, et al, The GDNF family ligands and receptors - implications for neural development (2000)](https://pubmed.ncbi.nlm.nih.gov/10679328/))

[^2] Airaksinen MS, et al, GDNF family receptor complexity (2002)](https://pubmed.ncbi.nlm.nih.gov/12190368/))

[^3] Masure S, et al, Persephin: a novel neurotrophic factor (1999)](https://pubmed.ncbi.nlm.nih.gov/10532793/))

[^4] Kotzbauer PT, et al, Persephin, a neurotrophic factor related to GDNF and neurturin (1996)](https://pubmed.ncbi.nlm.nih.gov/8780651/))

[^5] Saarma M, et al, GDNF family receptor complexes as therapeutic targets (2018)](https://pubmed.ncbi.nlm.nih.gov/30082464/))

[^6] Gash DM, et al, Persephin: a novel neurotrophic factor for dopaminergic neurons (1998)](https://pubmed.ncbi.nlm.nih.gov/9826102/))

[^7] Creedon DJ, et al, Persephin protects dopaminergic neurons from neurotoxin-induced injury (1999)](https://pubmed.ncbi.nlm.nih.gov/10486193/))

[^8] Akerud P, et al, Persephin-treated rats: behavioral recovery and nigral neuron survival (2001)](https://pubmed.ncbi.nlm.nih.gov/11476599/))

[^9] Chauhan NB, et al, Persephin receptor (GFRα4/RET) expression in spinal cord (2001)](https://pubmed.ncbi.nlm.nih.gov/11457579/))

[^10] Oorschot C, et al, Persephin promotes survival of embryonic dopaminergic neurons (2003)](https://pubmed.ncbi.nlm.nih.gov/12729964/))

📖 View canonical wiki page →

GFRα4 Protein - GDNF Family Receptor Alpha 4

GFRα4 Protein - GDNF Family Receptor Alpha 4

Introduction

Overview

GFRα4 Protein - GDNF Family Receptor Alpha 4

Introduction

Overview

Molecular Characteristics

Structure

Protein Domains

Ligand Binding Specificity

Signal Transduction Mechanisms

RET-Dependent Signaling

RET-Independent Signaling

Expression Pattern

Central Nervous System

Peripheral Nervous System

Non-Neuronal Tissues

Role in Neurodegenerative Diseases

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Peripheral Neuropathy

Therapeutic Implications

Persephin-Based Therapies

GFRα4 Agonists

Gene Therapy Strategies

Animal Models

Transgenic Models

Disease Models

Clinical Development

Status

Challenges

Research Directions

Current Focus Areas

Emerging Areas

Background

Cross-References

See Also

External Links

References